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Cytotoxic agentsDevelopment of efﬁcient and safe cancer therapy is one of themajor challenges of themodernmedicine. Over the
last few years antibody–drug conjugates (ADCs) have become a powerful tool in cancer treatment with two of
them, Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine), having recently been
approved by the Food and Drug Administration (FDA). Essentially, an ADC is a bioconjugate that comprises a
monoclonal antibody that speciﬁcally binds tumor surface antigen and a highly potent drug, which is attached
to the antibody via either cleavable or stable linker. This approach ensures speciﬁcity and efﬁcacy inﬁghting cancer
cells, while healthy tissues remain largely unaffected.
Conventional ADCs, that employ cysteine or lysine residues as conjugation sites, are highly heterogeneous. This
means that the species contain various populations of the ADCs with different drug-to-antibody ratios (DARs)
and different drug load distributions. DAR and drug-load distribution are essential parameters of ADCs as they
determine their stability and efﬁcacy. Therefore, various drug-loaded forms of ADCs (usually from zero to eight
conjugated molecules per antibody) may have distinct pharmacokinetics (PK) in vivo and may differ in clinical
performance. Recently, a signiﬁcant progress has been made in the ﬁeld of site-speciﬁc conjugation which resulted
in a number of strategies for synthesis of the homogeneous ADCs. This review describes newly-developedmethods
that ensure homogeneity of the ADCs including use of engineered reactive cysteine residues (THIOMAB), unnatural
amino acids, aldehyde tags, enzymatic transglutaminase- and glycotransferase-based approaches and novel
chemical methods. Furthermore, we brieﬂy discuss the limitation of these methods emphasizing the need for
further improvement in the ADC design and development.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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The idea behind targeted anticancer therapies originates from the
‘magic bullet concept’ which was introduced at the beginning of the
20th century by Paul Ehrlich, the father of modern immunology and
chemotherapy. Ehrlich proposed that in order to reduce adverse effects
of toxic molecules on healthy tissues drugs should be selectively deliv-
ered to disease-causing cells (Strebhardt and Ullrich, 2008). Realization
of Ehrlich's vision became possible when production of monoclonal
antibodies, that provide excellent speciﬁcity and high afﬁnity of binding
to antigens, was developed in the mid-70s (Kohler andMilstein, 1975).
Monoclonal antibodies against tumor speciﬁc antigens can be labeled
either with a particle emitting radioisotope (radioimmunotherapy,
RIT) or with a highly potent drug resulting in antibody–drug conjugates
(ADCs). Both strategies allow one to speciﬁcally destroy cancer cells.
Nowadays, two radio-immunoconjugates, 131I-tositumab (Bexxar®,
GlaxoSmithKline) and 90Y-ibritumomab tiuxetan (Zevalin®, Bayer
Schering Pharma AG/Spectrum Pharmaceuticals) are approved for treat-
ment of non-Hodgkin's lymphoma (Bodet-Milin, 2013; Chamarthy
et al., 2011). Currently,177Lu and 211At radio-immunoconjugates targeting
colon cancer are intensively investigated (Eriksson et al., 2012, 2014).
Conjugation of cytotoxic payloads to monoclonal antibodies, that bind
tumor cell surface antigens, enables to target and deliver drugs to cancer
cells leaving normal cells largely unaffected. Importantly, this approach
takes advantage of highly potent cytotoxic molecules that would be too
toxic for use in conventional chemotherapy. Therefore, ADCs constitute
a precise and powerful tool in ﬁghting cancer. The research in the ADC
ﬁeld has been extremely intense in the past 10 years. This resulted
in the approval of two ADC therapeutics, brentuximab vedotin
(Adcetris®, Seattle Genetics) and ado-trastuzumab emtansine
(Kadcyla®, Genentech) by the Food and Drug Administration (FDA) in
2011 and 2013, respectively. Furthermore, approximately 40 ADCs are
currently undergoing clinical trials. Despite the tremendous progress
in ADC technology, further improvement is necessary to ensure safetyTable 1
Current site-speciﬁc conjugation methods.
Company/institution Conjugation strategy
Genentech
Seattle Genetics
Conventional lysine and cysteine conjugation
Lewis Phillips et al. (2008) and Senter and Sievers (2012)
Sutro Biopharma
Ambrx
Incorporation of unnatural amino acids into antibodies
Axup et al., 2012 and Zimmerman et al., 2014
National Cancer
Institute
Incorporation of selenocysteine into antibodies
Hofer et al. (2009)
Rinat-Pﬁzer Streptoverticillium mobaraense transglutaminase (mTG)
Speciﬁcally recognizes and modiﬁes genetically introduced glutam
(LLQGA) with a primary amine-containing linker-drug module
Strop et al. (2013)
Sanoﬁ-Genzyme Glycoengineering
Site-speciﬁc introduction of sialic acid with the use of galactosyl- a
sialytransferases
Zhou et al. (2014a)
Innate Pharma Microbial transglutaminase (MTGase)
Enzymatic conjugation of a primary amine-containing linker/linker
to glutamine speciﬁcally recognized by MTGase
Dennler et al. (2014)
Redwood Bioscience Formylglycine generating enzyme (FGE)
Converts cysteine located in the CXPXR consensus sequence to formy
Drake et al. (2014)
UCL Cancer Institute Next generation maleimides (NGMs)
Rebridge reduced interchain disulﬁde bonds of a native antibody
Schumacher et al. (2014)
PolyTherics Bis-alkylating reagents
Rebridge reduced interchain disulﬁde bonds of a native antibody
Badescu et al. (2014)and efﬁcacy of ADC-based products. One of the main challenges in
ADC design is homogeneity of ADC molecules. Currently available
ADCs are heterogeneous as they have zero to eight drug molecules per
antibody. It has been reported that heterogeneity of ADC species can in-
ﬂuence its pharmacokinetics (PK) and in vivo performance (Hamblett
et al., 2004; Jackson et al., 2014; Junutula et al., 2008a; Strop et al.,
2013). Therefore, biotechnology companies and academic units are in-
tensely focused on establishing novel reliable methods for site-speciﬁc
conjugation of cytotoxic agents to monoclonal antibodies (Table 1).
The outcome of their effort has recently been summarized in a few ex-
cellent reviews. Agarwal and Bertozzi (2015) and Cal et al. (2014) in
their articles discuss details of chemical aspects of site-speciﬁc conjuga-
tionmethods. Behrens and Liu (2014) and Panowksi et al. (2014) give a
general overviewonwell-deﬁnedADCdesign andproduction. In our re-
view we describe novel approaches towards homogeneous ADC, in-
cluding those that are not discussed in above-mentioned reviews.
2. Conventional conjugation methods and their limitations
Essentially, an ADC contains three main components: a monoclonal
antibody, a cytotoxic agent and a synthetic linker that is required to attach
the drug to the antibody. Conventional conjugation methods employ
surface-exposed lysine or interchain cysteine residues as attachment
sites for linker-drug molecules. A human IgG comprises about 100 lysine
residues. Mass spectrometry analysis of the huN901-DM1 antibody–drug
conjugate revealed that potentially 40 of them can be modiﬁed with the
DM1 cytotoxic drug (Wang et al., 2005). Lysine conjugation results in
zero to eight drug molecules per antibody. This implicates that a tremen-
dous number of over one million different ADC species can be generated
using this unspeciﬁc approach (Wang et al., 2005).
Cysteine conjugationoccurs after reductionof four interchaindisulﬁde
bonds, which leads to eight thiol groups that are available for linker-drug
molecules. In this strategy, drugs are coupled to even number of cysteines
(2, 4, 6 or 8) (Hamblett et al., 2004; Sun et al., 2005; Willner et al., 1993).Antibody
engineering
Chemistry
(non-enzymatic reactions)
DAR
Not
required
Thiol–melimide
Primary amine-NHS-ester
(coupling linker-drug to a native antibody)
3–4
Required Click chemistry
oxime ligation (coupling linker-drug to an
incorporated unnatural amino acid)
2
Required Selenol-maleimide
Selenol-iodoacetamide
(coupling linker-drug to an incorporated
selenocysteine)
2
ine tag
Required – 1.8–2
nd
Not
required
Oxime ligation
(coupling linker-drug to a modiﬁed Fc glycans)
~1.6
-drug module
Required Thiol–maleimide
Click chemistry
(coupling drug to linker-antibody)
2
lglycine (FGly)
Required Hydrazino-iso-Pictet-Spengler ligation
(coupling linker-drug to FGly)
2
Not
required
Reaction between thiols and leaving groups of
the NGM linker-drug
(coupling linker-drug to a native antibody)
1
2
3
4
Not
required
Micheal addition and elimination reactions
(coupling linker-drug to a native antibody)
2
4
Fig. 1. Conventional conjugation methods. A. Cysteine conjugation relies on a chemical
reaction between the cysteine thiol group and the maleimide group present in the linker.
B. Lysine conjugation takes advantage of SMCC, which contains an amine-reactive
N-hydroxysuccinimide (NHS ester) and a sulfhydryl-reactive maleimide group.
The NHS-ester groups react with primary amines, including lysines to form stable amide
bonds, which results in a linker-modiﬁed antibody. In the second reaction, the thiol
group present in the drug module forms a nonreducible thioether bond with the
maleimide group of the linker.
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hundred differently drug-loaded species are present in ADC mixtures.
Although both approaches generate heterogeneous ADCs, linking
drugs through interchain cysteine residues generates signiﬁcantly
fewer ADC species than using lysines. Two FDA-approved ADC thera-
peutics, brentuximab vedotin (Adcetris®) and ado-trastuzumab
emtansine (Kadcyla®), are produced by lysine and cysteine conjuga-
tions, respectively.
Brentuximab vedotin (Adcetris®) used for the treatment of Hodgkin
lymphoma and systemic anaplastic large cell lymphoma (ALCL) was
generated by linking a highly cytotoxic inhibitor of microtubule poly-
merization, monomethyl auristatin E (MMAE), to the anti-CD30monoclonal antibody cAC10. These two components are coupled
through a cathepsin-cleavable linker [e.g. valine–citrulline (vc) dipep-
tide linker] that undergoes proteolysis in lysosomes releasing MMAE
molecules inside target cells (Doronina et al., 2003). The covalent
bond between the linker-drug module and the antibody employs modi-
ﬁcation of disulﬁde bonds that link the antibody's heavy and light chains
together (Senter and Sievers, 2012; Sun et al., 2005; van de Donk and
Dhimolea, 2012) (Fig. 1A). Importantly, removing disulﬁde bonds from
an antibody does not affect its functions (Andersen and Reilly, 2004). In
addition, interchain disulﬁde bridges are more prone to reduction than
intrachain disulﬁde bridges (Schroeder et al., 1981; Willner et al.,
1993). This allows one to generate free thiol groups under mild reducing
conditions leaving antibody intact. The thiol groups can be then used as
conjugation sites for cytotoxic drugmolecules. Adcetris® containsmainly
2, 4 and 6 molecules of vcMMAE per antibody and less than 10% (for
each) of unconjugated antibodies and the ADCs with eight drugs
(Senter and Sievers, 2012; Sun et al., 2005). Despite heterogeneity,
brentuximab vedotin successfully passed pivotal phase 2 clinical trials
with the objective response rate (ORR) of 75% (including 34% of com-
plete responses) for Hodgkin lymphoma patients (Younes et al., 2012)
and ORR of 86% (including 57% of complete responses) for patients
with relapsed or refractory systemic ALCL (Pro et al., 2012).
Trastuzumab, better known under its trade name Herceptin®
(Genentech), is an anti-HER2 monoclonal antibody that is used in
HER2-positive metastatic breast cancer. It was approved by the FDA in
1998 having become the ﬁrstmonoclonal antibody used in the targeted
cancer therapy. Because the combination of trastuzumab with chemo-
therapy regiment [e.g. with microtubule-targeting drugs (Lewis
Phillips et al., 2008)] enhances its antitumor effects, a trastuzumab-
based ADC was developed by Genentech. Ado-trastuzumab emtansine
(Kadcyla®) is made up of trastuzumab and a highly potent derivative
of maytansine DM1 linked together by the use of SMCC [Succinimidyl-
4-(N-maleimidomethyl)cyclohexane-1-carboxylate] (Barginear
et al., 2012; Lewis Phillips et al., 2008; LoRusso et al., 2011; Peddi
and Hurvitz, 2013) (Fig. 1B). In this case, the DAR ranges from 3.2
to 3.8 DM1 molecules per antibody with a smooth, uniform distribu-
tion of the cytotoxic payload (Kim et al., 2014; Lewis Phillips et al.,
2008).
Gemtuzumab ozogamicin (Mylotarg®,Wyeth/Pﬁzer) was approved
for the treatment of acute myeloid leukemia (AML) by the FDA in 2000
having become the ﬁrst ADC in clinical use. However, due to the lack of
clinical beneﬁts and possible toxicity observed in the post-approval
clinical trials, Mylotarg® was withdrawn from the US and European
markets in 2010 (Ricart, 2011). Similarly to Kadcyla, Mylotarg® was
generated through lysine conjugation. However, unlike Kadcyla®,
Mylotarg® contained 50% of the antibody conjugated to four to six
drugmolecules with the remaining antibody having been unconjugated
(Bross et al., 2001). This characteristic of Mylotarg®, along with insufﬁ-
cient stability of a hydrazone linker,might have contributed to its failure
in the therapy of AML.
Apart from cysteines and lysines, other residues, including N-terminal
serine and threonine, can be used for site-speciﬁc protein modiﬁcation.
These hydroxyl-containing amino acids can be converted to a highly
reactive carbonyl group through periodate oxidation and then reacted
with an aminooxy- or hydrazide-functionalized compounds resulting
in oxime or hydrazone linkage, respectively (Gaertner and Offord,
1996; Geoghegan and Stroh, 1992; Zhou et al., 2014b). So far, this strat-
egy was successfully applied for site-speciﬁc PEGylation of interleukin-
8, G-CSF and interferon β-1b (Gaertner and Offord, 1996; Zhou et al.,
2014b).
3. Why homogeneity of ADCs is important?
Conventional methods that are used for ADC synthesis result in a
heterogeneous mixture of ADC species that differ in the drug-to-
antibody ratio (DAR) and drug load distribution/location (Hamblett
778 A.M. Sochaj et al. / Biotechnology Advances 33 (2015) 775–784et al., 2004; Wang et al., 2005). Typically, zero to eight drug molecules
can be attached to the antibody. Consequently, heterogeneous ADCs
may contain both unconjugated and overloaded antibodies.
Unconjugated antibodies compete with drug-loaded species for antigen
binding that can diminish the activity of ADC therapeutics. On the other
hand, a high degree of the antibodymodiﬁcationmay result in antibody
aggregation, increased toxicity, decreased stability and shorter half-life
of ADCs in the circulation. Experimental work has revealed that the
optimal DAR for most ADCs is four drug molecules per antibody as
this ratio represents a compromise between cytotoxicity and pharma-
cokinetic stability of ADCs (Hamblett et al., 2004; Senter and Sievers,Fig. 2. Antibody engineering-based methods. A. Interchain cysteine to serine substitutions en
heterogeneity of ADCs B. Conjugation of cytotoxic drugs to THIOMABs. Capped THIOMABs (gl
oxidation prior to the conjugation reaction C and D. Incorporation of unnatural amino acid (e.g. p
of cytotoxic agent.2012). The characterization of an ADC composed of a highly cytotoxic
drug monomethyl auristatin E (MMAE) and the anti-CD30 monoclonal
antibody cAC10 demonstrated that although in vitro tumor cell killing
activity of this ADC increased with increasing drug load (IC50 values
drug load 8 b drug load 4 b drug load 2), the in vivo antitumor activity
of a species containing fourMMAEmoleculeswas comparablewith a spe-
cies containing eight MMAE molecules at equal antibody doses. In addi-
tion, the higher drug-loaded species exhibited faster renal clearance
(Hamblett et al., 2004).
Recently, a signiﬁcant role of a drug-conjugation site has been re-
ported (Shen et al., 2012; Strop et al., 2013). A study carried out byable to conjugate cytotoxin to the remaining cysteines, which signiﬁcantly reduces the
utathione or cysteine attached to the engineered cysteine) undergo reduction and partial
-acetylphenylalanine, pAcPhe) or selenocysteine (Sec) allows for site-speciﬁc conjugation
779A.M. Sochaj et al. / Biotechnology Advances 33 (2015) 775–784Shen et al. (2012), demonstrated that the physicochemical properties of
the conjugation site, including solvent-accessibility and a net electric
charge of the local environment, can have a functional impact on ADC
stability and biological activity in vivo. A thiol-reactivemaleimide linker
was used to couple MMAE to the cysteines that were engineered at
three different sites into the therapeutic anti-HER2 antibody (the
THIOMAB technology described in Section 4.1.2). Plasma stability,
pharmacokinetics and efﬁcacy of the obtained conjugateswere analyzed,
revealing signiﬁcant differences between the variants. The highest rate of
drug release was observed for the variant having MMAE conjugated to a
highly solvent accessible cysteine, whereas conjugation to a partially bur-
ied cysteine located in a positively charged region resulted in the most
stable ADC variant (Shen et al., 2012).
These ﬁndings allowed one to propose the model assuming, that
conjugation sites with high solvent accessibility promote a rapid loss
of conjugated thiol-reactive linkers in plasma due to maleimide ex-
change with reactive thiols in albumin, free cysteine or glutathione
(Alley et al., 2008). On the contrary, partially solvent accessible site
with a positively charged environment supports linker stability by
preventing this exchange reaction (Shen et al., 2012). Importantly, this
model applies to the ADCs that contain melamine linkers, and other
linkers may be differently sensitive to the physicochemical properties
of conjugation site. The importance of conjugation site was also
described by Strop et al. (2013)who compared two distinct conjugation
sites on the anti-M1S1 antibody C16. The sites were located on the
heavy and light chains of the antibody. The analysis of pharmacokinetic
properties of these two ADC species showed that in the ADC species
utilizing conjugation site on the light chain was more stable in rat
serum than the ADC species utilizing conjugation site on the heavy
chain (Strop et al., 2013). In this case, chemical stability of a trans-
glutaminase linkage was preserved in rat andmouse sera, suggesting
another conjugation site-dependent mechanism that contributes to
drug loss.
Optimization of a drug-to-antibody ratio and drug load distribution/
location emerges as an important consideration for ADC design. Ideally,
the ﬁnal ADC-based product should exclusively contain an optimally
drug-loaded form of the conjugate. Overall, only homogeneous and re-
producible ADCs can provide a therapeutic tool that has predictable
properties and batch-to-batch consistency.
4. Site-speciﬁc conjugation methods
4.1. Antibody engineering-based methods
4.1.1. Reducing the number of interchain disulﬁde bonds
Cysteine conjugation can result in homogeneous ADCs when all
interchain cysteines are coupled to drug molecules. A good example of
such ADC is a conjugate of the anti-CD30 monoclonal antibody cAC10
and monomethyl auristatin E (MMAE) developed by Doronina et al.
(2003) and Francisco et al. (2003). This cAC10-vcMMAE conjugate
contained eight drug molecules per antibody, which represents the
highest drug load that can be obtained by the use of interchain cysteines
as conjugation sites (Doronina et al., 2003; Francisco et al., 2003).
However, the optimal in vivo performance was observed with the four
drug-loaded form (Hamblett et al., 2004). The ﬁrst attempt to generate
homogeneous ADCswith a ﬁxed stoichiometry of two and four drugs per
antibody at deﬁned sites was described by McDonagh et al. (2006).
Selected interchain cysteines derived from three or two bisulﬁde bonds
were mutated to serines which resulted in the variants of the antibody
cAC10 with either two or four remaining accessible cysteines (Fig. 2A).
Following reduction, the variants with the reduced number of interchain
cysteines were conjugated to vcMMAE. Received highly homogeneous
species were compared to the heterogeneous ADCs, which were based
on the native cAC10 antibody (McDonagh et al., 2006).
The study demonstrated that the engineered ADCs with deﬁned
sites and stoichiometries of drug attachment had similar antitumoractivity, tolerability and pharmacokinetics as the ADCs with the same
(average) DAR but heterogeneous drug attachment sites. Nevertheless,
decreasing the number of drugmolecules coupled to the antibody from
four to two led to drop in efﬁcacy and increase in tolerability, whichwas
consistent with previous reports (Hamblett et al., 2004). Overall, these
observations suggested that the stoichiometry of drug attachment is a
more critical determinant of ADC properties than is the site of drug
attachment and conjugate homogeneity (McDonagh et al., 2006).
Noticeably, this hypothesis may be limited to conjugates generated
with the use of interchain disulﬁde bonds of IgG1 which are all located
in the highly solvent accessible hinge region (Liu and May, 2012).
4.1.2. Engineered cysteine mutants
The THIOMAB strategy is based on reactive cysteine substitutions at
carefully selected positions in the constant domains of the antibody Fab
region which is not involved in antigen binding. This allows one to
obtain conjugates with deﬁned site and stoichiometry and preserves
interchain disulﬁde bridges intact. The key success factor of this strategy
is the identiﬁcation of proper substitution sites in which introducing
reactive cysteine residue does not interfere with antibody function
and structure. For this purpose, the Phage Elisa for Selection of Reac-
tive Thiols (PHESELECTOR) was developed (Junutula et al., 2008b).
Reactive cysteine residues were introduced at various positions into a
trastuzumab-Fab (hu4D5Fab) used as a model system. The variants
were displayed on phage and screened for reactive cysteines that do
not interfere with antigen binding. This screening tool allowed one to
identify 10 residues that should be suitable for cysteine substitution
and site-speciﬁc conjugation (Junutula et al., 2008a, 2008b).
The antibodies containing engineered reactive cysteine residues
at identiﬁed positions were named THIOMABs. The THIOMAB variant
of anti-MUC16 antibody, with heavy chain alanine 114 (HC-A114)
substituted with cysteine, was used to generate the anti-MUC16
THIOMAB-drug conjugate (TDC) which was then compared with the
conventional anti-MUC16 antibody–drug conjugate (ADC). Importantly,
the anti-MUC16 THIOMAB exhibited equivalent antigen binding to the
original anti-MUC16 antibody which further conﬁrmed the results of
the PHESELECTOR screen. The site-speciﬁc conjugation of vcMMEA to
the anti-MUC16 THIOMABwas achieved by the reduction and partial re-
oxidation of this THIOMAB which gave two free thiol groups at position
114 in the heavy chains followed by the reaction of these thiols with the
maleimide group present in the linker-drug module (Fig. 2B). The con-
ventional cysteine conjugation method was utilized to couple MMAE
to the original anti-MUC16 antibody. In vitro and in vivo cytotoxicity as-
says showed that both conjugates, the anti-MUC16 TDC and ADC, had
comparable antitumor activity, although the ADC had almost twofold
higher drug load than the TCD (~3.5 drug molecules per anti-MUC16
antibody, ~2 drug molecules per anti-MUC16 THIOMAB). Safety studies
of the anti-MUC16 TDC and ADC carried out in rats and cynomolgus
monkeys showed that the adverse effects, including impaired functions
of the liver and lowwhite blood cell count, were far more pronounced in
the case of anti-MUC16ADC treatment (Junutula et al., 2008a).Moreover,
renal clearance of anti-MUC16 TDC is slower than that of the anti-MUC16
ADC in a rat model. Similar results demonstrating that the TDC version of
trastuzumab-DM1 conjugate was equally efﬁcient at the same dose as its
ADC counterpart and yet less toxic to animals suggest that the THIOMAB
strategy provides homogeneous conjugates with improved therapeutic
index in comparison to the conventional ADCs (Junutula et al., 2010).
4.1.3. Unnatural amino acids incorporation
The genetic code encodes 20 common amino acids, but it can be ex-
panded to accommodate additional amino acids. This can be accom-
plished by the generation of an orthogonal tRNA/aminoacyl-tRNA
synthetase (aaRS) pair, that site-speciﬁcally incorporates a desired
unnatural amino acid (e.g. p-acetylphenylalanine, pAcPhe) into nascent
polypeptides in the response to an amber stop codon (UAG) placed in a
gene of interest (Lemke, 2014; Wang, 2003; Wang et al., 2001).
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come a promising tool in ADC design (Kim et al., 2013). This approach
was successfully employed by Axup et al. (2012), who generated site-
speciﬁc auristatin conjugates of trastuzumab (a monoclonal anti-HER2
antibody). The amber stop codon was introduced in the heavy chain
of full-length IgG of trastuzumab at position 121 replacing alanine
(HC-A121X). The antibody was co-expressed with an orthogonal
Escherichia coli tyrosyl tRNA/aaRS pair in Chinese hamster ovary
(CHO) cell culture. In these settings, pAcPhe was loaded onto the
amber tRNA by the aaRS and then speciﬁcally incorporated in the
amber site in the heavy chain of trastuzumab. Following puriﬁcation,
the antibody was coupled to the auristatin F derivative containing a ter-
minal alkoxy-amine group by an oxime ligation through the engineered
pAcPhe residues (Fig. 2C). The analysis of antitumor potency and phar-
macokinetics of this site-speciﬁc ADC conﬁrmed its efﬁcacy, speciﬁcity
and stability in blood serum.
Very recently, the use of unnatural amino acid in ADC productionwas
further developed by Zimmerman et al. (2014) (Sutro Biopharma), who
discovered a novel variant of theMethanococcus jannaschii tyrosyl tRNA
synthetase with a high activity and speciﬁcity towards the unnatural
amino acid para-azidomethyl-L-phenylalanine (pAMF) and established
a cell-free protein expression platform for production of high yields of an-
tibodies containing a site-speciﬁc incorporation of pAMF.
4.1.4. Selenocysteine incorporation
Incorporation of selenocysteine can be an alternative to the unnatu-
ral amino acids platform. Selenocysteine (Sec) is called the 21st amino
acid and exists in all kingdoms of life as a component of selenoproteins
(Johansson et al., 2005). Currently, there are 25 known selenoproteins
in mammals and selenocysteine that have been found in the active
site of those that have been attributed a catalytic function (Kryukov
et al., 2003). Selenocysteine contains selenium in the place of sulfur
(pKa 5.2) which makes it more reactive towards electrophiles (e.g.
maleimide or iodoacetamide) in acidic conditions (pH 5.2) than its
classical counterpart, cysteine (pKa 8.3) (Kim et al., 2013). This
chemical property of selenocysteine was used to selectively couple
maleimide and idoacetamide containing agents to the antibodies
with genetically engineered selenocysteine (Hofer et al., 2009; Li et al.,
2014) (Fig. 2D). Selenocysteine is incorporated into nascent polypep-
tides in the response to the opal stop codon (UGA) when a stem–loop
structure, known as the Sec insertion sequence (SECIS), is present in
the 3′ untranslated regions (UTRs) in eukaryotes and in archaea, or im-
mediately downstream of UGA in bacteria (Kryukov et al., 2003). Fur-
thermore, selenocysteine can be engineered into a classical protein by
insertion of the UGA codon and the SECIS at the 3′ of the gene encoding
this protein. The proof of concept experiments involving conjugation of
ﬂuorescent probes, biotin and biotin-polyethylene glycol (biotin-PEG)
to antibodies resulted in the fully functional conjugates having deﬁned
sites and stoichiometries of agent attachment, which demonstrates that
incorporation of selenocysteine provides a novel technology for gener-
ating homogeneous ADCs (Hofer et al., 2009; Li et al., 2014).
4.2. Enzymatic methods
4.2.1. Glycotransferases
IgGs are N-glycosylated at the conserved asparagine 297 (N297)
within the CH2 domain of the Fc fragment. The human Fc N-linked
glycans consist of a variety of glycoforms, which are referred as G0, G1
and G2 and contain 0, 1 and 2 terminal galactoses, respectively. Qasba
and coworkers developed a mutant of β1,4-galactosyltransferase,
β1,4Gal-T1-Y289L, which facilitates transfer of modiﬁed galactose hav-
ing a chemical handle at the C2 position (GalNAz or 2-keto-Gal) onto
the G0 glycoform to enable site-speciﬁc IgG modiﬁcation (Boeggeman
et al., 2009; Ramakrishnan and Qasba, 2002). Recently, an additional
mutation was introduced to the mutant resulting in a double mutant
that exhibits higher catalytic activity in the presence of Mg2+ than inthe presence of Mn2+ that can be toxic to cells. This allows labeling of
surface glycans on living cells, which can be further used in glycome
studies (Mercer et al., 2013). Importantly, enzymatic modiﬁcation of
the Fc glycans followed by a chemically-driven attachment of a cytotox-
ic molecule provides a feasible way to generate site-speciﬁc ADCs
(Boeggeman et al., 2009; Zhu et al., 2014). Initially, this strategy was
used to link biotinylated or a ﬂuorescent dye carrying derivatives to
therapeutic monoclonal antibodies. The ﬁrst enzymatic step involved
a release of all terminal galactoses using β1,4-galactosidase from
Streptococcus pneumonia, which resulted in a homogeneous population
of G0 glycoform. Then, degalactosylated glycans were modiﬁed by the
attachment of galactose containing chemically reactive functional
group, e.g. C2-keto-Gal or GalNAz catalyzed by β1,4Gal-T1-Y289L. Func-
tionalized biotin and ﬂuorescent dyes were subsequently linked to the
modiﬁed glycans using an appropriate chemistry, e.g. oxime ligation
(Boeggeman et al., 2009). Most notably, in a recent study this approach
has been evaluated for generation of an ADC comprising a newly iden-
tiﬁedmonoclonal antibody against HER2 receptor, m860, and auristatin
F (Zhu et al., 2014). The resulting highly homogeneous bioconjugate ex-
hibited cell-killing activity speciﬁcally against HER2-positive tumor
cells demonstrating that glycoengineering technology can be potential-
ly applied in ADC design and production.
Glycoengineering has also been employed in a recently described
method for the synthesis of site-speciﬁc ADCs, in which sialic acid was
used as a chemical handle for a selective conjugation (Zhou et al.,
2014a). This was achieved by the incorporation of sialic acid units
onto the native glycans of trastuzumab using a mixture of β1,4-
galactosyltransferase (Gal T) and α2,6-sialyltransferase (Sial T). Prior to
reaction with aminooxy-functionalized linker-drug, sialic acid residues
were oxidized under mild conditions, which led to the conversion of the
acidic groups to aldehyde groups. The resulting modiﬁed antibody was
reactedwith the cytotoxicmodule via the oxime ligation (Fig. 3A). Thede-
scribed procedure was evaluated by conjugating trastuzumab to two dif-
ferent cytotoxins, monomethylauristatin E (MMAE) and dolastatin 10
(Zhou et al., 2014a). The obtained conjugates were signiﬁcantlymore ho-
mogeneous when compared to their counterparts that were generated
using the conventional conjugation through interchain cysteines (de-
scribed in Section 2). Moreover, the glycoengineered ADCs exhibited a
comparable antitumor activity to that of the conventional ADCs despite
lower drug load (Zhou et al., 2014a).4.2.2. Transglutaminases
Microbial transglutaminase (MTGase) catalyzes the formation of an
isopeptide bond between the γ-carbonyl amine group of glutamines
and the primary amine of lysine that is accompanied by the release of
ammonia (Grifﬁn et al., 2002). The coupling activity ofmicrobial (bacte-
rial) transglutaminase has been applied to modify antibodies, including
synthesis of homogeneous ADCs (Dennler et al., 2014; Jeger et al., 2010;
Strop, 2014; Strop et al., 2013). Dennler et al. (2014) has recently
proposed a chemo-enzymatic conjugation strategy, which yielded high-
ly homogeneous trastuzumab-MMAE conjugate with a DAR of 2. This
strategy involved two steps: enzymatic, employing peptide-N-
glycosidase F (PGNase F) and MTGase followed by chemical reaction,
with the use of strain-promoted azide-alkyne cycloaddition (SPAAC)
chemistry. PGNase was used to remove a glycan attached to asparagine
residue (N297) adjacent to the conjugation site, glutamine 295 (Q295).
Glutamine 295 within the heavy chain (HC) of IgGs was previously
shown to be speciﬁcally recognized by MTGase, which enabled a site-
speciﬁc conjugation with an exact DAR of 2. A small azide linker, con-
taining a primary amine group, was coupled to Q295 of the deglycosyl-
ated antibody by MTGase. This enzymatic reaction was followed by a
Cu(I)-free cycloaddition of the alkyne unit-containing auristatin
(MMAE) module (Fig. 3B). The SPAAC reaction was relatively fast (a
few hours) with a 2.5-fold excess of the cytotoxic module and resulted
in uniform and functional ADCs (Dennler et al., 2014).
Fig. 3. Enzymatic methods A. Modiﬁcation of that native glycans on asparagine 297 in the Fc region using galactosyl- (Gal T) and sialyltransferases (Sial T) results in the incorporation of
sialic acid units. Following oxidation of sialic acid, drug molecule is coupled to the aldehyde group through oxime ligation. B. Microbial transglutaminase (MTGase) incorporates a small
azide linker speciﬁcally onto glutamine 295. Cytotoxic molecule is conjugated to the linker using click chemistry (SPAAC). C. Genetically engineered aldehyde tag (CXPXR) is recognized
and modiﬁed by formylglycine-generating enzyme (FGE). Introduced formylglycine (FGly) can be then subjected to click chemistry or hydrazone ligation with a cytotoxic module.
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Type I sulfatases, the enzymes that hydrolyze sulfate esters, are acti-
vated by the oxidation of their active site cysteine to the aldehyde-
containing Cα-formylglycine residue. This unusual co-translational modi-
ﬁcation is conferred by the formylglycine (FGly)-generating enzymes
(FGEs). FGEs recognize and modify a short consensus sequence, CXPXR
(where X is any amino acid), in the context of heterologous proteins.
This observation was applied to generate a novel platform for site-
speciﬁc ADCs based on the incorporation of FGly into monoclonalantibodies (Drake et al., 2014; Rabuka et al., 2012). Introducing the alde-
hyde tag sequence (e.g. LCTPSR) into a protein of interest along with co-
expression of FGE allows one to produce the aldehyde-tagged protein in
mammalian or bacterial expression system (Rabuka et al., 2012). Follow-
ing the production of the modiﬁed protein, a chemical approach must be
employed to couple a cytotoxic agent to the aldehydemoiety of FGly.
In the proof of concept experiments that demonstrated the feasibility
of this approach, aminooxy- or hydrazide-functionalized molecules
were successfully attached to the model proteins (Rabuka et al.,
782 A.M. Sochaj et al. / Biotechnology Advances 33 (2015) 775–7842012). Recently, the aldehyde tag strategy was further developed by
Drake et al. (2014), who used hydrazino-iso-Pictet-Spengler (HIPS)
chemistry to couple cytotoxic maytansine to the aldehyde-tag con-
taining trastuzumab (Fig. 3C). The HIPS ligation results in the forma-
tion of a stable, covalent C–C bond, which is more stable in
physiological condition than hydrazone or oxime ligation products
(Agarwal et al., 2013). Furthermore, the study showed that the alde-
hyde tag can be introduced in the various locations within the antibody
without affecting the stability and antitumor activity of the obtained
ADCs (Drake et al., 2014).4.3. Chemical approaches
The majority of methods for site-speciﬁc conjugation of cytotoxic
drugs to antibodies described above involved a modiﬁcation of these an-
tibodies prior to conjugation reaction. Recently, a universal chemically-
driven strategy for the synthesis of homogeneous ADCs has been
proposed. This novel approach takes advantage of bis-sulfone reagents
that undergo bis-alkylation to conjugate both thiols of the two cysteine
residues that were obtained through the reduction of native disulﬁde
bonds (Badescu et al., 2014; Del Rosario et al., 1990) (Fig. 4A). Previously,
thismethodhas been successfully applied for the site-speciﬁc conjugation
of PEG to the therapeutic proteins, including human interferon α-2b
and a human CD receptor-blocking antibody fragment (Fab)
(Shaunak et al., 2006). To validate the use of bis-sulfone reagents in
ADC production, a cytotoxic payload (MMAE) was loaded onto bis-sul-
fone module containing a small PEG spacer of 24 repeat units, which
was used in order to increase solubility and improve pharmacokinetics
of the conjugates (Badescu et al., 2014). The resulting cytotoxicmodules
were coupled to the reduced trastuzumab (the therapeutic anti-HER2
antibody). Chemical conjugation yielded 78% of ADCs with a drug-to-
antibody ratio (DAR) of 4 and less than 1% of unconjugated antibody.
Notably, by adjusting conditions of the conjugation reaction, the desired
average DAR can be obtained. The MMAE-trastuzumab conjugates
retained antigen binding and stability, and exhibited antitumor activityFig. 4. Chemical approach (A) and photoactivation of protein Z (B). A. A bis-sulfone reagent con
sulﬁde bond. B. Photoactive protein Z is conjugated speciﬁcally to the Fc region of the antibody u
Z would enable to generate site-speciﬁc ADC by the use of UV light.both in vitro and in vivo. A similar method, relying on the next gener-
ation maleimides (NGMs) for site-speciﬁc conjugation in a controlled
manner, was described in a recent study by Schumacher et al. (2014).
The NGMs are maleimides, which are substituted in the 3- and 4-
positions with leaving groups, including bromide anion (Br−) and
thiophenol anion (PhS−). This chemical modiﬁcation of maleimides
facilitates a reaction with two nucleophilic thiol groups derived from a
reduced disulﬁde bridge (Schumacher et al., 2014). Recently, the strat-
egy based on the reaction between leaving groups and interchain cyste-
ines has been further developed. Maruani et al. (2015) used a
dibromopyridazinedione construct with two orthogonal clickable
handles to enable herceptin modiﬁcation with both a cytotoxic drug
and a ﬂuorophore. This approach resulted in a highly stable and homo-
geneous (DAR 4:1) ADC. Therefore, a chemoselective dual click strategy
might be successfully applied in ADC production (Maruani et al., 2015).4.4. Photoactive protein Z
Conjugation of a photoactive protein Z to antibodies has recently
emerged as a new, unconventional approach towards the synthesis of
uniform ADCs. Protein Z is a small (58 amino acids), helical protein
derived from the IgG-binding B domain of protein A. Notably, protein
Z, called also Z domain, binds most of IgG isotypes speciﬁcally within
the CH2–CH3 region of the Fc fragment with high afﬁnity (Nilsson
et al., 1987). Recently, 13 variants of protein Z with a UV active unnatu-
ral amino acid, benzoylphenylalanine (BPA), engineered into different
locations have been constructed (Hui and Tsourkas, 2014). BPA enables
to covalently couple protein Z to the antibody of interest upon exposure
to longwavelength UV light (365 nm) (Fig. 4B). The variants were eval-
uated in terms of their efﬁciencies of photo-conjugation to various na-
tive IgGs. Two of them, L17BPA and K35BPA, underwent coupling
reaction with the highest efﬁciency, ranging from 65% to 95% within
1 h of UV exposure, and therefore are good candidates for ADC design
(Hui and Tsourkas, 2014). The technology, which allows to introduce a
click-chemistry compatible azide group onto C-terminus of photoactivetaining a cytotoxic moiety conjugates both thiol groups derived from a reduced native di-
pon exposure to longwavelength UV. Coupling a cytotoxic drug to the photoactive protein
783A.M. Sochaj et al. / Biotechnology Advances 33 (2015) 775–784protein Z by expressed protein ligation (EPL) has recently been
described (Hui et al., 2014). Therefore, development of ADCs based on
the optimized photoactive protein Z seems to be a matter of time.
5. Conclusions and perspectives
According to a number of studies, homogeneity of ADCs is a crucial de-
terminant of their potency and safety. Synthesis of uniform ADCs limits
batch-to-batch variability, which is important for manufacturing process
aswell as for clinical applications. Commercially available ADCs, Kadcyla®
and Adcetris® are a breakthrough in the treatment of metastatic breast
cancer and CD-30 positive lymphomas, respectively. Nevertheless, their
therapeutic potential may be not fully exploited due to heterogeneity.
Since publication of the ﬁrst studies demonstrating that site-speciﬁc con-
jugation improves the therapeutic index of ADCs (Junutula et al., 2008a;
McDonagh et al., 2006), a number of approaches towards generation of
homogeneous ADCs have been developed. Initially, these strategies in-
volved engineering of native antibodies either by removingor introducing
cysteines (described in Section 4.1). Antibody engineeringwas further in-
vestigated, which resulted in the methods that were based on incorpora-
tion of genetically encoded unnatural amino acids or selenocysteine
(Axup et al., 2012; Hofer et al., 2009). In the recent years, several enzy-
matic methods have also been proposed (described in Section 4.2). How-
ever, the majority of these methods still requires antibodies to be
modiﬁed either by single-site mutation or introduction of genetically
engineered tags (e.g. aldehyde tag and glutamine tag), which makes
them relatively complex (Dennler et al., 2014; Drake et al., 2014;
Rabuka et al., 2012; Strop et al., 2013). Additionally, the position of intro-
duced amino acid or amino acid sequence needs to be carefully optimized
to ensure stability of conjugates and avoid aggregation of antibodies
(Drake et al., 2014; Shen et al., 2012; Strop et al., 2013). Novel chemical
methods provide a rapid synthesis of homogeneous ADCs that are based
on native, non-engineered antibodies (described in Section 4.3). Impor-
tantly, they are universal as, similarly to the conventional cysteine conju-
gation, they employ interchain cysteines as conjugation sites (Badescu
et al., 2014; Schumacher et al., 2014). Noticeably, in contrast to the re-
moval of disulﬁde bridges that takes place in the conventional cysteine
conjugation, the use of bis-sulfone reagents and the next generation
maleimides (NGMs) causes re-bridging of disulﬁde bonds, which leaves
the antibody structurally intact andmayhelp to preserve its effector func-
tions (Romans et al., 1977; Seegan et al., 1979).
A variety of conjugation approaches that have been developed in a
relatively short period of time show that ADC design is a very challenging
ﬁeld (Perez et al., 2014). Apart from the drug–antibody coupling strate-
gies, new targeting molecules, including antibody-derived fragments
and single-domain antibodies, are evaluated for clinical use. Thanks to
advanced antibody engineering techniques, alternative formats of anti-
bodies can be conveniently produced. The most popular antibody conﬁg-
urations include Fabs, scFvs, diabodies, triabodies and minibodies
(Alvarenga et al., 2014; Nelson, 2010). A distinct type of antibody
fragment, called nanobody or VHH, can be derived from a single-chain
camelid antibody comprising a single variable domain and two constant
domains. Importantly, it has been demonstrated that diabodies,
minibodies as well as nanobodies can be successfully used as cytotoxic
drug carriers (Cortez-Retamozo et al., 2004; De Meyer et al., 2014; Kim
et al., 2008; Perrino et al., 2014). Currently, Ablynx Inc. and Spirogen are
collaborating on novel pyrrolobenzodiazepines (PBDs)-nanobody
conjugates for cancer treatment. Moreover, bispeciﬁc antibodies and
bispeciﬁc antibody fragments, which bind two distinct antigens or epi-
topes on the same antigen, have recently emerged as very promising
targetingmolecules (Spiess et al., 2015). Biotechnology and pharmaceuti-
cal companiesworldwide are developing a new class of ADC therapeutics
based on bispeciﬁc antibodies (Garber, 2014; Lameris et al., 2014). Inten-
sive research work on different aspects of ADCs leads to a further im-
provement of cytotoxic conjugates, which is necessary to accelerate
their passage from a proof of concept stage to clinical application.Acknowledgments
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